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Abstract
Background: Praziquantel (PZQ) is the drug compound of choice in the control and treatment of schistosomiasis. PZQ is
administered as a racemate, i. e. 1:1 mixture of enantiomers. The schistosomicidal activity arises from one PZQ-enantiomer,
whereas the other enantiomer does not contribute to the activity. The WHO’s Special Programme for Research and Training
in Tropical Diseases (TDR) has assigned the low-cost preparation of pure schistosomicidal (2)-PZQ a key priority for future
R&D on PZQ, but so far this transition has not happened. PZQ has two major administration drawbacks, the first being the
high dose needed, and its well documented bitter and disgusting taste. Attempts of taste-masking by low-cost means have
not been successful. We hypothesized that the non-schistosomicidal component in PZQ would be the main contributor to
the unpleasant taste of the drug. If the hypothesis was confirmed, the two major administration drawbacks of PZQ, the high
dose needed and its bitter taste, could be addressed in one go by removing the component contributing to the bitter taste.
Methods and Findings: PZQ was separated into its schistosomicidal and the non-schistosomicidal component, the absolute
stereochemical configuration of (2)-PZQ was determined to be (R)-PZQ by X-ray crystallography, and the extent of
bitterness was determined for regular racemic PZQ and the schistosomicidal component in a taste study in humans.
Finding: The schistosomicidal component alone is significantly less bitter than regular, racemic PZQ.
Conclusion: Our hypothesis is confirmed. We propose to use only the pure schistosomicidal component of PZQ, offering the
advantage of halving the dose and expectedly improving the compliance due to the removal of the bitter taste. Therefore,
(R)-PZQ should be specifically suitable for the treatment of school-age children against schistosomiasis. With this finding, we
would like to offer an additional incentive to the TDR’s recommendation to switch to the pure schistosomicidal (R)-PZQ.
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Introduction
Praziquantel [1] (PZQ) is the drug compound of choice in the
control and treatment of schistosomiasis [2], in fact, it is the only
commercially readily available drug. So far, no backup compound
for PZQ of comparable efficacy and breadth of application is
available. Clinically relevant resistance has not been observed,
however differences in responses of PZQ-resistant and -susceptible
Schistosoma mansoni to PZQ in vitro have been described [3]. PZQ is
included in the WHO Model List of Essential Drugs [4] and is at the
core of numerous schistosomiasis control programmes. The WHO’s
strategy for schistosomiasis control [5] aims at reducing morbidity
through treatment with PZQ, with a focus on periodic treatment of
school-age children and adults considered to be at risk. School-age
children are seen as a high-risk group for schistosome infections
because they are more susceptible to infection in cases where their
increased nutritional needs are not adequately met, might be
compromised by helminth infections in their cognitive development,
and are continuously exposed to contaminated soil and water but
probably less aware of the need for good personal hygiene [6].
While the safety and efficacy against all schistosoma species are
outstanding, PZQ has two major administration drawbacks, the
first being the high dose needed, 40 mg PZQ/kg bodyweight:
Dosages in children are determined by measurement of children’s
heights using tablet poles, and range from one to five 600 mg-
tablets for one treatment. Especially young children have been
reported not to be able to swallow these 600 mg tablets [7]. The
second drawback is PZQ’s well documented bitter and disgusting
taste, which can lead to gagging or vomiting if tablets are chewed
contrary to recommendation [8]. In veterinary medicine, the oral
delivery of PZQ to taste-sensitive companion animals like cats is
known to be a challenge. Traditional methods of taste-masking,
like the addition of aromas or sugar, are ineffective for PZQ. The
bitterness of PZQ even led to PZQ’s use as a bitter model drug
compound in the effectiveness testing of sophisticated and
expensive taste-masking techniques like micro-encapsulation [9]
or drug active coating [10]. Apart from anecdotal evidence [2], we
are not aware of reports of low compliance among children treated
within schistosoma programmes due to the bitter taste. However,
we have to assume that the unpleasant taste of PZQ does not lead
to a treatment situation which school-age children would enjoy.
PZQ is administered as a racemate, i. e. 1:1, mixture of two
compounds of identical constitution but non-superimposable
mirror-image configuration, so called enantiomers. The straight-
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reason for the use of the racemate, although it has been known for
years that the schistosomicidal activity mainly relies in one PZQ-
enantiomer, designated (2)-PZQ (alternatively termed levo-PZQ, l-
PZQ, sometimes L-PZQ), whereas the other enantiomer, designated
(+)-PZQ (alternatively termed dextro-PZQ, d-PZQ), does not
contribute to the activity [11–13] (Figure 1). From this perspective,
only half of the drug compound administered is in fact the drug
active, whereas the other half must be considered molecular ballast,
which has to be metabolized and excreted while not contributing to
the schistosomicidal activity. To the best of our knowledge, no
clinical studies in humans exist if and how non-schistosomicidal (+)-
PZQalonecontributestothesideeffectsknownofracemicPZQ,but
this may be assumed: Upon incubation of PZQ and both
enantiomers with isolated rat hepatocytes, additional metabolites
were detected resulting from the non-contributing (+)-PZQ [14].
Various methods of producing the pure schistosomicidal component
(2)-PZQ exist, which are considerably more expensive than the
production of racemic PZQ itself. So far, the potential alone to
administer half the current dose by replacing racemic PZQ by (2)-
PZQ did not lead to a production process for (2)-PZQ comparable
in costs for racemic PZQ.
In the context of the WHO’s Global Plan to combat NTDs
[15], the Special Programme for Research and Training in
Tropical Diseases (TDR) set up an incentive for further R&D work
by emphasizing the low-cost preparation of pure schistosomicidal
(2)-PZQ (see also the schistosomiasis research collaborative
community within The Synaptic Leap [16]) as a key priority for
future R&D on PZQ [17]. Three pharmacological goals for the
development were stated: (1) same dose of (2)-PZQ as currently in
regular, racemic PZQ, with smaller tablet size and less frequent/
severe adverse events, (2) higher dose of (2)-PZQ with similar
tablet size and possibly similar adverse event profile as current
treatment which could reduce the probability of or delay the
development of resistance, or (3) a combination of these two
objectives. As we already mentioned, a smaller tablet size would be
more suitable for the treatment of children. Taking into account
that the WHO’s strategy specifically aims at school-age children,
we were intrigued by the question whether the taste disadvantage
of PZQ could be turned into an additional incentive to introduce
(2)-PZQ against schistosomiasis as the drug active of choice.
Background to our consideration was the well-documented fact
that in most cases taste experiences depend on the stereochemical
configuration of the agent [18], i. e. the taste buds react
enantioselectively–like all natural receptors which are composed
of chiral constituents like L-amino acids. We hypothesized that
(2)-PZQ and (+)-PZQ would contribute to the bitter taste to a
different extent, and that the non-schistosomicidal (+)-PZQ would
be the main or sole contributor to the disgusting taste.
Surprisingly, no public knowledge exists on the tastes of the two
enantiomers. We prepared schistosomicidal (2)-PZQ, assigned the
stereochemical configuration by X-ray crystallography, and
determined the extent of bitterness for regular racemic PZQ
versus the schistosomicidal component (2)-PZQ in a taste study in
humans. We chose this comparison over the comparison of (2)-
PZQ to non-schistosomicidal (+)-PZQ because the latter alone
does not have any role in a treatment situation. Also the
pharmacological studies by others had compared racemic PZQ
to (2)-PZQ, and not (+)-PZQ to (2)-PZQ [19].
Methods
Preparation and stereochemical assignment of (2)-PZQ
Although effective synthetic methods for the enantioselective
preparation of PZQ have been reported [20], we opted for the
direct enantioseparation of the racemate yielding gram quantities
of both optical forms. The preparative scale chromatography was
performed on microcrystalline cellulose triacetate using methanol
as the mobile phase, conditions under which the enantiomer
having the negative optical rotation emerged first from the column
[21]. After crystallisation from methanol/water, (2)-PZQ was
obtained in enantiomeric excess .99%, as determined by HPLC
(column used Chiralcel OD-H). No residual other enantiomer (+)-
PZQ was detected in this sample. X-ray structural analysis, using
Cu-Ka radiation, of a monoclinic crystal in hemi-hydrate form
obtained from said fraction by crystallization from methanol/
water unequivocally proved the R-configuration of the molecule by
measuring Friedel pairs and the Flack parameter (x=20.1(3))
(Figure 2). Further details of the crystal structure analysis are
available on request from the CCDC (www.ccdc.cam.ac.uk)
quoting the names of the authors and journal citation.
Determination of the bitterness value
The bitterness values of racemic PZQ and its schistosomicidal
component (R)-PZQ were determined according to the European
Pharmacopoeia [22] by comparison with quinine hydrochloride,
Figure 1. Molecular structures of the two mirror-image compo-
nents of PZQ; asymmetric carbon atom highlighted in yellow.
doi:10.1371/journal.pntd.0000357.g001
Author Summary
Schistosomiasis, or Bilharzia, is a parasitic disease caused
by flatworms, which affects about 200 million people
worldwide. Praziquantel (PZQ) is the drug compound of
choice in the control and treatment of this disease. Only
half of the drug dose currently administered actually has
activity against schistosomiasis, whereas the other half has
no activity. Therefore, the WHO has assigned the low-cost
preparation of the pure active component a key priority
for future PZQ research and development. PZQ has two
major administration drawbacks, the first being the high
dose needed, the second its well documented bitter taste.
Attempts of masking the unpleasant taste have not been
successful. We hypothesized that the non-active compo-
nent in PZQ would be the main contributor to the
unpleasant taste of the drug. We determined the extent of
bitterness for regular PZQ compared to the pure active
component in a taste study in humans. We found that the
pure active component alone is significantly less bitter
than regular PZQ. This new finding should serve as an
additional incentive for the PZQ research and develop-
ment community to provide a low-cost, large-scale
preparation route to the pure active component of PZQ.
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5. The bitterness value is
defined by the European Pharmacopoeia as the reciprocal of the
concentration of a solution in a dilution series of a compound, a
liquid or an extract that still has a bitter taste. Concentrations of
solutions used in the tests ranged from 1.69610
28 to 1.0610
24 g/
mL. A test panel consisting of sixteen members was assembled.
Although children comprise the treatment target group no children
were included in the test panel. All panel members were adults
completely untrained in performing sensory tests. To correct for
individual differences in tasting bitterness amongst the panel
members a correction factor was determined for each panel member
by preparing dilutions of quinine hydrochloride. The mouth was
rinsed with water before tasting. The dilution with the lowest
concentration having a bitter taste was determined by taking 10 mL
oftheweakestsolutionintothemouthandpassingitfromsidetoside
over the back of the tongue for 30 seconds. If the solution was not
found to be bitter, the panellist had to spit out and wait for one
minute before the mouth was rinsed again with water. After
10 minutes, the next dilution in order of increasing concentration
was tasted. The correction factor k for each panel member was
calculated according to the European Pharmacopoeia by k=n/5,
where n is the number of millilitres of the stock solution in the
dilution of the lowest concentration that is judged to be bitter. One
panel member detected bitterness already in pure water, and was
therefore excluded from the test panel. Dilutions of the test
compounds racemic PZQ and (R)-PZQ were prepared and tasted
by the remaining fifteen members of the test panel in the same
manner as described for quinine hydrochloride. The bitterness value
as experienced by each member was calculated according to the
European Pharmacopoeia taking the individual-related correction
factor into account by Y6k/X60.1, where Y is the dilution factor of
the dilution, and X is the number of millilitres of the respective
dilution which, when diluted to 10 mL with water, still has a bitter
taste. The bitterness value of the test compounds resulted from
calculating the average of the individual values.
Requested statement: Informed written consent was obtained
from all panelists to participate in this taste study. As a taste study,
and not a medical study in the sense of the WMA Declaration
of Helsinki, it did not require approval of an independent
review board (highly diluted preparations were tasted and spat
out–they were not ingested). Nevertheless, it was conducted
according to the principles of the WMA Declaration of Helsinki
where applicable.
Results
The results of the determination of bitterness values are shown
in Table 1. Remarkable is the variation of the individuals’ results
as indicated by the relative standard deviation and the dispersion
of the results in the box-and-whisker diagram (Figure 3). In
contrast to the average, the medians of the results, as depicted in
the box-and-whisker diagram, are different from each other. The
observed variation was probably provoked by the test panel
consisting of untrained members only [23]. Thirteen out of fifteen
panel members found (R)-PZQ to taste less bitter than racemic
PZQ. Although no statistical test is required or proposed by the
Figure 2. X-ray crystallographic structure of (R)-PZQ; asymmetric carbon atom highlighted in yellow.
doi:10.1371/journal.pntd.0000357.g002
Table 1. Bitterness values for racemic PZQ and
schistosomicidal (R)-PZQ
Member of the test panel Racemic PZQ (R)-PZQ
Individual bitterness values/10
5
A 1.03 0.14
B 0.46 0.11
C 7.85 0.68
D 7.85 0.09
E 1.92 1.23
F 1.71 0.27
G 355 592
H 177 178
I 250 0.37
J 0.62 0.25
K 14.5 0.29
L 39.4 0.10
M 5.52 0.41
N 7.23 0.14
O 0.55 0.28
Bitterness value (average) 58.1 51.6
Standard deviation 110 156
Relative standard deviation 191% 303%
doi:10.1371/journal.pntd.0000357.t001
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release 9.1.3, SAS Institute Inc., Cary, NC, USA) was conducted
to investigate the observed difference between the compounds.
Considering the small sample size and the nature of the data which
does not justify the assumption of a normal distribution, a
nonparametric, distribution-free method was chosen. On the 5%
level of significance, Wilcoxon’s Signed Rank Test (two-sided)
resulted in a significant difference between the taste of racemic
PZQ and (R)-PZQ (p=0.0107). This result was confirmed by the
Sign Test (two-sided, p=0.0018).
In addition to the quantitative determination of the bitterness
values, qualitative taste sensations were noted by the members of
the test panel for each compound. For racemic PZQ, all panel
members commonly observed the sensation of an unpleasant
chemical or metallic taste or a taste circumscribed best by old
rubber. On the other hand, for (R)-PZQ the panellists commonly
described the sensation of a moderate chemical taste, comparable
to that of a polyethylene or a rubber pipe. Although the tastes were
not recognized alike across the test panel, for the majority of the
test panel we can state that (R)-PZQ had a less unpleasant taste
compared to racemic PZQ.
Discussion
The schistosomicidal component of regular PZQ, (R)-PZQ has
a less unpleasant taste compared to racemic PZQ, which was
found to be comparably bitter or unpleasant. It can be assumed
that the disgusting taste of racemic PZQ stems from the non-
schistosomicidal component, (S)-PZQ. Removing the latter from
currently used racemic PZQ therefore not only offers the chance
to halve the dose, with the potential to decrease the number or size
of the tablets, but also addresses the second disadvantage of
regular, racemic PZQ-its unpleasant taste. With this finding and its
publication we would like to offer an additional incentive to focus
work of the PZQ R&D community on further decreasing the cost
of production of (R)-PZQ with the goal to switch to pure (R)-PZQ
as a replacement for racemic PZQ for the treatment of school-age
children against schistosomiasis.
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